Crossmark

Comment on “Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?”

Crossref DOI link: https://doi.org/10.1007/s00432-026-06608-4

Published Online: 2026-09-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bhise, Manish R. https://orcid.org/0000-0002-3848-2549
Akotkar, Akshay

Bhandari, Shweta

Gite, Kuldip V.
License Information

Text and Data Mining valid from 2026-09-07

Version of Record valid from 2026-09-07
More Information

Article History

Received: 19 August 2026

Accepted: 21 August 2026

First Online: 7 September 2026

Declarations

Conflict of interest: The authors declare that they have no conflict of interest.

Ethical approval: Not applicable, as this manuscript is a commentary on a previously published article.

Consent to participate: Not applicable.

Consent for publication: All authors have read and approved the final version of the manuscript and consent to its publication.

Generative AI statement: No generative artificial intelligence tools were used in the preparation, writing, analysis, interpretation, or revision of this manuscript.

Document is current

Any future updates will be listed below